revisiting farnesyltransferase inhibitors for head and neck cancer
Published 4 years ago • 135 plays • Length 1:05Download video MP4
Download video MP3
Similar videos
-
0:30
07 -what does a farnesyltransferase inhibitor (fti) do? - interview with dr. fadlo khuri
-
2:22
06 - farnesyltransferase enzyme and cancer - interview with dr. fadlo khuri
-
1:26
phase i trial of copanlisib nivolumab in patients with richter’s transformation or transformed fl
-
3:48
final data of eftilagimod alpha and pembro in pd-1/pd-l1 inhibitors resistant 2l metastatic nsclc
-
3:30
final results from fight-202: pemigatinib for patients with fgfr-mutated advanced cholangiocarcinoma
-
2:57
fgfr driver genetic alterations in nsclc
-
3:05
alliance a021501: preoperative mfolfirinox /- hypofractionated rt for pancreatic cancer
-
1:21
rhea's story: inhibitor testing
-
3:36
outcomes of patients with newly diagnosed crlf2-rearranged b-all
-
2:04
shining a spotlight on cancer cells
-
4:17
vt3989 is safe and well tolerated in patients with advanced malignant mesothelioma and nf2m cancers
-
27:37
next generation egfr inhibitors for mutations and disease
-
3:08
engineering an inhibitor-resistant human csf1r variant for microglia replacement
-
2:40
the rapid growth of fgfr2 inhibitors: pemigatinib in fight-202
-
0:42
dr. fidler discusses osimertinib in egfr-mutated lung cancer
-
56:32
stag2 mutations in the pathogenesis of human cancer | dr. todd waldman
-
23:30
cancer cell growth: revisiting a gordian knot - dr hans ake fabricius of cell receptor
-
34:30
how has breast cancer treatment evolved over the last 2 decades?